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Abstract. Cardiovascular diseases are the most common 
cause of death in the world. The development of heart failure is 
mainly due to the loss of cardiomyocytes following myocardial 
infarction and the absence of endogenous myocardial repair. 
Numerous studies have focused on cardiac stem cells (CSCs) 
due to their therapeutic benefit, particularly in the treatment of 
heart failure. It has previously been demonstrated that CSCs are 
able to promote the regeneration of cardiomyocytes in animals 
following myocardial infarction. However, the underlying 
mechanism(s) remain unclear. This review mainly discusses 
the cardioprotective effect of CSCs and the effect of CSCs on 
the function of cardiomyocytes, and compares the efficacies 
of CSCs from rats, mice and humans, thereby contributing to 
an improved understanding of CSCs as a promising treatment 
option for heart failure.
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1. Introduction
It was previously considered that the regeneration of the heart 
was impossible to affect on a cellular level and that the heart 
was a terminally differentiated organ with no potential for 
regeneration. The general opinion was that cardiomyocytes 
rapidly proliferate during the embryonic and fetal period but 
exit the cell cycle soon after birth (1-3). However, cardiac 
stem cells (CSCs) have been successfully identified in the 
hearts of rats, mice, dogs and humans (4-9). Thus, the heart's 
own regenerative potential opens up a new paradigm in 
cardiology.
A number of studies have demonstrated that the application 
of stem cells by injection into the cardiac muscle or coronary 
arteries as part of bypass surgery or cardiac catheterization 
procedure increases the contractility of perfused hearts 
following myocardial infarction (10-15). 
Experimental results have suggested that CSCs are able to 
differentiate into three major cardiac cell populations, including 
cardiomyocytes, smooth muscle cells and endothelial cells (4). 
Animal experiments have shown the positive effect of CSCs 
following a heart attack (9). Thus, CSCs may be the optimal 
stem cells for the treatment of heart failure. Therefore, this 
review mainly discusses the cardioprotective effect of CSCs 
and the effect of CSCs on the function of cardiomyocytes, and 
compares the efficacies of CSCs from rats, mice and humans.
2. New opinion of the heart's own regenerative potential
It is only in the last 15 years that evidence of mitosis has been 
observed in hearts with acute and chronic ischemic cardio-
myopathy (16-18), idiopathic dilated cardiomyopathy (17) and 
chronic aortic stenosis (19). 
Studies have revealed that mitosis occurred in, on average, 
14 of 106 myocytes (17), i.e., it is necessary to investigate 
~350 mm2 tissue to identify a single cell undergoing mitosis 
using a confocal microscope (20). Cell division mainly 
occurs in mononuclear cells, which account for ~75% of the 
cells in the myocardium, and is somewhat rare in binucleated 
cells (21). Binucleated cells are usually larger than mononu-
clear cells. The authors observed that human cardiomyocytes 
>30,000 mm3 were no longer able to enter the cell cycle (19). 
It has also been reported that young and old cardiomyo-
cytes exist simultaneously in the rat heart (22,23). Cells with 
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stem cell surface antigens and myocardium‑specific transcrip-
tion factors were identified in the myocardium. These cells 
expressed connexin and cadherin and were thus coupled with 
mature myocytes via gap junctions (23). Therefore, contrary 
to previous theories, the heart appears to possess regenerative 
potential (24).
In addition, chimerism (the presence of genetically 
different cells in the same organism) has been observed in the 
human myocardium following heart transplantation (26,27). 
Several samples were collected from the atria and ventri-
cles of a male patient who had received a heart from a female 
donor in 2002 and a Y‑chromosome was identified in samples 
by fluorescence in situ hybridization (FISH). In a sample, 
obtained primarily from the atria, there were more cells with 
stem cell antigens following transplantation. Of these cells, 
12-16% had a Y chromosome (28). These results suggest that 
circulating stem cells are capable of settling in the heart or that 
the heart is able to attract stem cells.
This view of the heart's own regenerative potential opens 
up novel avenues of therapy for heart failure. There is now 
moderate hope that the severity of heart failure may be reduced 
by exogenous or endogenous stem cell therapy.
3. Markers for the characterization of cardiac stem cells
Stem cells have been detected in a number of tissues, including 
the blood, skin, central nervous system, liver, gastrointestinal 
tract and skeletal muscles (29). CSCs have been observed in 
the hearts of rats, mice, dogs and humans (4-9). CSCs may 
be identified by various surface antigens. The best known are 
c-Kit (30), Sca-1 (31), Islet-1 (Isl-1) (32) and multidrug resis-
tance protein-1 (MDR1) (33), as shown in Fig. 1.
Isl-1 is a transcription factor used to identify the cell 
population which constitutes a substantial proportion of the 
embryonic heart. Isl-1 expression is downregulated when the 
cells assume a differentiated phenotype, suggesting that this 
transcription factor identifies CSCs (34,35).
c-Kit, or stem cell factor receptor, is a protein from the 
receptor tyrosine kinase (RTK) family and is expressed mostly 
in hematopoietic stem cells. c-Kit is crucial in the proliferation 
and differentiation of stem cells (36) and is used as a stem cell 
marker.
The stem cell antigen Sca-1 is also expressed in hema-
topoietic stem cells and is commonly used as a stem cell 
marker (37).
GATA-4 is a cardiac transcription factor and marker of 
CSCs which is essential in the development of the heart (38). 
The inhibition of GATA-4 expression results in the inhibition 
of the terminal differentiation of cardiomyocytes (39). 
Atrial natriuretic peptide (ANP) and brain natriuretic 
peptide (BNP) are considered to be cardiac‑specific markers. 
Their main functions are the reduction of plasma volume and 
the lowering of blood pressure. ANP and BNP are the main 
antagonists of the renin-angiotensin-aldosterone system. 
ANP is a polypeptide synthesized almost exclusively in the 
cardiomyocytes of the atria and ventricles during hypertrophy 
of the ventricles. ANP is secreted into the circulating blood in 
response to atrial stretch, hypoxia or increased plasma osmo-
larity. BNP is another a polypeptide mainly expressed in the 
ventricles and atria. The release of BNP occurs particularly 
in the expansion chambers of the heart due to overload and 
congestion of the heart. Therefore, ANP and BNP are also 
defined as cardiac‑specific hypertrophic markers (40).
Cardiotrophin-1 is a cytokine and member of the inter-
leukin-6 family. It is expressed mainly in the heart, skeletal 
muscle, prostate and ovaries and, to a lesser degree, in the 
lung, kidney, pancreas, thymus, testis and small intestine. 
Studies have shown that cardiotrophin-1 is detectable only 
Figure 1. Markers (c‑kit, Sca‑1 and Isl‑1) used for the identification of cardiac stem cells. In addition, the surface markers of ‘side population cells’ express 
MDR-1. 
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during embryogenesis, primarily in the developing mouse 
heart (41). Asai et al. demonstrated that the human heart 
secreted cardiotrophin-1 into the peripheral circulation via the 
coronary sinus (42).
The protein α-actin is located in muscle tissue and is a 
major component of the contractile apparatus. Thus, α-actin is 
also studied as a marker for muscle cells and cardiac myocytes.
β-myosin heavy chain (β-MHC) occurs in the adult heart 
where it forms an integral part of the protein myosin and hence 
the contractile apparatus. In addition to β-MHC, another 
isoform of myosin heavy chain, α-MHC, is also expressed in 
cardiac muscle (43). 
The endothelial nitric oxide synthase (eNOS) enzyme 
belongs to the family of NO synthases. It catalyzes the forma-
tion of nitric oxide from the amino acid L-arginine and is 
involved in the regulation of blood pressure. eNOS was first 
detected in endothelial cells but was later identified in cardiac 
myocytes, platelets and brain (44).
4. Cardioprotective effect of cardiac stem cells
CSCs may be derived from animal and human hearts. As with 
the adult stem cells from bone marrow progenitor cells, CSCs 
are considered to be a potential treatment option for the failing 
heart. Decisive advantages of CSCs are the possibility of 
using autologous cells and their ethical acceptability. Several 
studies have examined their ability to improve cardiac func-
tion following myocardial ischemia. Beltrami et al isolated 
CSCs from adult rat hearts and injected them into rat hearts 
five hours after myocardial infarction, which led to regenera-
tion of the infarcted myocardium (4). Bearzi et al reported 
similar results in the infarcted myocardium after human 
CSCs were locally injected into immunodeficient mice and 
immunosuppressed rats (45). In animal models of myocar-
dial infarction, the intramyocardial injection of hepatocyte 
growth factor (HGF) and insulin-like growth factor 1 (IGF-1) 
activated the formation of cardiomyocytes and coronary 
vessels within the infarcted area through their binding to 
the receptors of the resident CSCs (8,46). The reduction of 
the infarct size and increase of the left ventricular ejection 
fraction were observed in a rat model when HGF was admin-
istered directly after acute myocardial infarction (47). CSCs 
and the intramyocardial injection of HGF and IGF-1 resulted 
in the regeneration of the infarcted area and newly formed 
myocardial tissue at 20 days after the induction of myocardial 
infarction in rat hearts (48). 
The mechanism underlying the effects described is not yet 
sufficiently understood. Initially, it was proposed that CSCs or 
their descendants directly replace the damaged heart tissue, 
for example, following myocardial infarction (4). However, 
CSCs may cause the release of certain factors by a paracrine 
mechanism to improve cardiac function and the remodeling 
process (49). Chimenti et al demonstrated that human CSCs 
secreted vascular endothelial growth factor (VEGF), HGF 
and IGF-1 after transplantion into immunodeficient mice 
following acute myocardial infarction. VEGF is also critical 
in the stem cell-mediated cardioprotective effect (50). In other 
studies, additional factors have been identified that may be 
partly responsible for mediating the cardioprotective effects, 
including sVCAM-1 (51) and interleukin-10 (52). It has also 
been shown that adult stem cells, particularly mesenchymal 
stem cells, produce a number of other cytokines, chemokines 
and growth factors, including matrix metalloproteinases 
(MMPs), tissue inhibitors of metalloproteinases (TIMPs), 
monocyte chemoattractant protein-1 (MCP-1), VEGF and 
interleukins (53). It has been demonstrated that cardiac 
overexpression of MCP-1 in mice results in a reduction of 
the infarct area and scar formation and an improvement 
in left-ventricular dysfunction and remodeling following 
myocardial infarction (54). Studies of mesenchymal stem cells 
have also shown that a significant release of VEGF and IGF‑1 
mediates anti-apoptotic and angiogenic effects and thus exerts 
a cardioprotective effect (55).
The granulocyte colony-stimulating factor (G-CSF) has 
been investigated in several studies to determine whether it 
causes stem cell mobilization and may thus exert a positive 
impact on cardiac regeneration following acute myocardial 
infarction. The subcutaneous administration of G-CSF would 
be less invasive than, for example, the intramyocardial or 
intracoronary administration of progenitor cells. Despite the 
successful mobilization of stem cells by G-CSF, neither a 
favorable effect on the left-ventricular function nor a reduction 
of the infarct size was observed in patients following myocar-
dial infarction and reperfusion (56).
In spite of all the previous studies, the exact cardioprotec-
tive mechanism of CSCs remains poorly understood since 
it is not possible to distinguish between an improvement in 
cardiac function and a direct effect on cardiomyocytes in the 
in vivo model. The prevalence of heart failure increases with 
advancing age, but it is debatable whether the function of stem 
cells is impaired with increasing age (57). 
5. Effect of cardiac stem cells on the function of 
cardiomyocytes
Numerous studies have been conducted to investigate the 
effect of CSCs on cardiomyocytes but the mechanism under-
lying the effect remains unknown. The theory that CSCs 
differentiate into cardiomyocytes directly in the injured 
heart tissue following myocardial infarction (4) has been 
increasingly displaced by the hypothesis that CSCs release 
various factors which affect the heart muscle and surrounding 
tissue (47,49). 
Kretlow et al revealed an age-associated impairment 
of the differentiation potential of stem cells obtained from 
the bone marrow of mice (58). By contrast, Smith et al 
reported that a significant increase in bone marrow stem 
cells correlated with increasing age and that the proliferation 
of hematopoietic stem and progenitor cells did not stop with 
increasing age in mice (59).
Several studies have already identified several cytokines 
and growth factors secreted by CSCs. Not all of these factors 
have confirmed cardioprotective effects and some cytokines 
even have cardiodepressant effects (60). However, certain 
factors appear to have a demonstrably positive effect on cardiac 
function. Other factors secreted by CSCs and other adult and 
mesenchymal stem cells with notable cardioprotective effects 
include transforming growth factor beta 1 (TGF‑β1), soluble 
vascular cell adhesion molecule 1 (sVCAM-1), interleukin-10, 
MCP-1 (54), MMPs and TIMPs. However, the effects of a 
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number of the previously identified factors on the function 
of cardiomyocytes have never been examined and therefore 
further studies are required to clarify which factors and 
mechanisms underlie the observed effects.
6. Effect of cardiac stem cells on cardiomyocytes from 
pressure‑loaded hearts
In examining the effect of CSCs on cardiomyocytes obtained 
from pressure-loaded hearts, it is notable that cardiomyocytes 
from spontaneously hypertensive rats, as well as those from 
rats with L‑NAME‑induced hypertension show no significant 
changes in their contractile function following a 24-h incu-
bation with CSCs. By contrast, following antihypertensive 
therapy with hydralazine, the 24-hour incubation with CSCs 
improved the contractile function at a frequency of 0.5 Hz and 
this improvement was 4.7±1.8% in the spontaneously hyper-
tensive rats. In the rats with L-NAME-induced hypertension 
which underwent subsequent antihypertensive treatment, the 
increase in the contractile function was 10.8±4.0%. The results 
demonstrate that antihypertensive therapy favors the effect of 
CSCs in cardiomyocytes from pressure-loaded hearts (61,62).
7. Comparison of the efficacy of cardiac stem cells from 
rats, mice and humans
The effects of CSCs on cardiac function have been investi-
gated in numerous animal models with positive results. A 
clinical trial in humans is currently underway concerning 
the therapeutic benefit of progenitor cells on reduced cardiac 
function following myocardial infarction. The effects of 
adult stem cells from the bone marrow on cardiac function 
following myocardial infarction have been evaluated in a 
number of clinical studies (63-66). The results of these studies 
demonstrated a decrease in infarct scarring, an improvement 
of the ejection fraction and a decrease in the left ventricular 
end-systolic volume. Therefore, it is likely that the effects of 
CSCs are comparable between animals and humans. For the 
isolation and culturing of CSCs, tissue samples from the heart 
rather than the entire heart were collected from humans, while 
the entire heart was used for mice and rats. This explains why 
the concentration of human CSCs required was significantly 
lower than that of rat CSCs to achieve a similar effect. A 
beneficial effect on the contractile function of cardiomyocytes 
may also be derived by the use of mouse heart, albeit at higher 
concentrations than are used for rat and human cells (62).
8. Conclusion
This review mainly discusses the cardioprotective effect of 
CSCs and the effect of CSCs on the function of cardiomyo-
cytes, and compares the efficacy of CSCs from rats, mice and 
humans, thereby contributing to an improved understanding 
of CSCs as a promising treatment option for heart failure. It 
has been demonstrated in animal models that CSCs are able 
to promote the regeneration of cardiomyocytes following 
myocardial infarction. This view of the heart's own regen-
erative potential opens up novel avenues of therapy for heart 
failure. There is now moderate hope that the severity of heart 
failure may be reduced by CSC therapy. 
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